MASP-2 Inhibitor Selective Lectin Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, such as Eculizumab, target downstream components of the complement system, failing to inhibit the initiation steps of complement activation, which can lead to tissue damage in various disease states, and there is a need for a more effective inhibitor that specifically targets the initiation of the complement cascade.
Innovation Solution
A monoclonal MASP-2 inhibitory antibody or fragment is used to selectively inhibit MASP-2-dependent lectin complement activation, while leaving the classical complement pathway intact, thereby preventing the adverse effects of complement activation in conditions like atypical hemolytic uremic syndrome and other disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If downstream complement inhibitors like Eculizumab are used, then complement-mediated tissue damage is reduced, but the initiation steps of complement activation are not inhibited
Solution Approach 1:
The patent extracts and targets the specific initiation step of the lectin pathway by inhibiting MASP-2, separating this function from the downstream complement components. This allows selective inhibition of complement activation initiation while preserving other immune functions, directly resolving the contradiction between reducing tissue damage and ensuring reliable inhibition of activation initiation.
Solution Approach 2:
The patent introduces MASP-2 as a specific intermediary target between the lectin pathway recognition molecules (MBL, ficolins) and the downstream complement components (C4, C2, C3). By targeting this intermediary enzyme, the invention achieves reliable inhibition of complement activation initiation while allowing controlled preservation of classical pathway function through C1q.
2Object-affected harmful factors
If broad complement inhibition is applied, then tissue damage is prevented, but classical complement pathway activation is also inhibited
Solution Approach 1:
The patent applies local quality by creating pathway-specific inhibition: the MASP-2 inhibitor selectively affects the lectin pathway while leaving the classical pathway (mediated by C1q and C1s) intact. This localized approach allows the system to maintain adaptability and versatility by preserving classical pathway activation for antibody-mediated immune responses while preventing harmful lectin pathway activation.
Solution Approach 2:
The patent segments the complement system into distinct controllable pathways by targeting MASP-2 specifically in the lectin pathway. This segmentation allows independent control of lectin and classical pathways, enabling selective inhibition of harmful lectin-mediated activation while preserving beneficial classical pathway functions for adaptive immune responses.
3Reliability
If MASP-2 inhibition is used to target lectin pathway, then lectin pathway activation is inhibited, but specificity of inhibition must be ensured
Solution Approach 1:
The patent uses MASP-2 as a specific intermediary target that is uniquely associated with the lectin pathway. The monoclonal antibody is designed to bind specifically to MASP-2, ensuring high measurement precision and specificity of inhibition. This specific targeting prevents off-target effects and ensures reliable lectin pathway inhibition while preserving classical pathway function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MASP-2 inhibitor effectively reduces the adverse effects of complement activation, specifically targeting the lectin pathway to prevent tissue damage and disease progression in conditions like aHUS, PNH, and other complement-mediated disorders, offering a more targeted approach than existing therapies.
Implementation Method 1
C4 is cleaved into two fragments, designated C4a and C4b, and, similarly, C2 is cleaved into C2a and C2b
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.